List of Excipients in Branded Drug ACCUPRIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	ACCUPRIL	quinapril hydrochloride	0071-0527	CANDELILLA WAX
Parke-Davis Div of Pfizer Inc	ACCUPRIL	quinapril hydrochloride	0071-0527	CROSPOVIDONE
Parke-Davis Div of Pfizer Inc	ACCUPRIL	quinapril hydrochloride	0071-0527	FERRIC OXIDE RED
Parke-Davis Div of Pfizer Inc	ACCUPRIL	quinapril hydrochloride	0071-0527	GELATIN
Parke-Davis Div of Pfizer Inc	ACCUPRIL	quinapril hydrochloride	0071-0527	LACTOSE
Parke-Davis Div of Pfizer Inc	ACCUPRIL	quinapril hydrochloride	0071-0527	MAGNESIUM CARBONATE
Parke-Davis Div of Pfizer Inc	ACCUPRIL	quinapril hydrochloride	0071-0527	MAGNESIUM STEARATE

Accupril Excipient Strategy and Commercial Opportunities for Quinapril Tablets

Last updated: September 7, 2026

Accupril is the U.S. brand for quinapril hydrochloride, an oral angiotensin-converting enzyme inhibitor marketed by Pfizer. Its core composition is mature, generic competition is established, and no meaningful U.S. compound or regulatory exclusivity remains. Commercial opportunity is therefore concentrated in reliable generic supply, nitrosamine-controlled manufacturing, excipient substitution, low-cost packaging, and selected reformulation or combination-product niches rather than conventional branded exclusivity.

What is Accupril and what excipient system does it use?

Accupril contains quinapril hydrochloride in immediate-release film-coated tablets equivalent to 5 mg, 10 mg, 20 mg, or 40 mg of quinapril. Quinapril is a prodrug converted in vivo to quinaprilat, the active ACE inhibitor metabolite. The product is indicated for hypertension and adjunctive treatment of heart failure [1].

The Accupril formulation uses a conventional compressed-tablet platform. Public labeling identifies excipient classes including:

Formulation element	Reported or typical Accupril function
Lactose	Diluent and tablet mass
Magnesium carbonate	Alkaline filler and microenvironment modifier
Gelatin	Binder or processing aid
Crospovidone	Superdisintegrant
Magnesium stearate	Lubricant
Hypromellose and hydroxypropyl cellulose	Film-coating polymers
Talc and titanium dioxide	Coating processing and opacity
Iron oxide pigment	Strength-specific color differentiation
Candelilla wax or related coating material	Surface finishing

The precise composition can vary by strength, manufacturing site, and labeling revision. Current product-specific formulation work should rely on the approved labeling and the reference listed drug record rather than historical secondary descriptions [1,2].

Why is magnesium carbonate strategically important?

Quinapril is an ester-containing ACE inhibitor and requires chemical-stability controls during processing and storage. An alkaline excipient such as magnesium carbonate can influence microenvironmental pH, moisture behavior, and degradation kinetics. It may help support tablet stability, but its use also affects:

• Blend uniformity and powder flow.
• Tablet hardness and disintegration.
• Dissolution across pH conditions.
• Compatibility with lactose and lubricants.
• The risk of strength-specific dissolution differences.
• Process scale-up and compression-force requirements.

A generic manufacturer should not assume that direct substitution with calcium carbonate, sodium bicarbonate, or another alkaline material will preserve bioequivalence. Each replacement requires comparative stability, dissolution, impurity, and bioequivalence assessment.

What excipients are protected by Accupril patents?

The historical Accupril patent estate does not provide a practical current barrier to generic development in the United States. Original quinapril composition and product patents expired years ago, and the FDA Orange Book does not provide a current U.S. exclusivity platform comparable to a recently approved small-molecule product [2,3].

The remaining commercial relevance of Accupril-related intellectual property is primarily technical:

1. Historical composition-of-matter and manufacturing patents may inform freedom-to-operate analysis.
2. Expired formulation patents can provide prior-art guidance for excipient selection.
3. Current generic manufacturers may hold unpublished process know-how involving granulation, coating, impurity control, or packaging.
4. New patents could arise from a genuinely differentiated formulation, but routine excipient substitution is unlikely to create durable exclusivity.

A new patent position would be more credible if it covered a defined technical result, such as a measurable reduction in quinapril degradation, improved dissolution after long-term storage, reduced nitrosamine formation, or a clinically useful modified-release profile.

When did Accupril lose exclusivity?

Accupril lost meaningful U.S. market exclusivity after expiration of its original small-molecule patent and regulatory exclusivity rights. The product has been exposed to generic competition for many years, and quinapril tablets are available through multiple generic manufacturers and labelers [2,3].

Exclusivity category	Current commercial position
New chemical entity exclusivity	Expired
Original quinapril composition patents	Expired
U.S. orphan exclusivity	Not applicable
Current pediatric exclusivity	None identified
Current Orange Book-listed exclusivity	No meaningful active exclusivity identified
Generic competition	Established
Biosimilar protection	Not applicable

The relevant regulatory pathway is an abbreviated new drug application, or ANDA, referencing quinapril hydrochloride tablets as the reference product. A conventional generic must demonstrate pharmaceutical equivalence and bioequivalence, comply with current manufacturing requirements, and address any applicable patent certifications.

What is the Orange Book status of Accupril?

Accupril is associated with FDA-approved quinapril tablet products, including NDA 019792 for the branded product. The FDA Orange Book records approved products, therapeutic equivalence information, patents, and exclusivity data. For a current transaction or launch decision, the latest electronic Orange Book and FDA Drugs@FDA records control [2,3].

The practical Orange Book conclusion is that Accupril is a mature, genericized product:

• No active branded exclusivity is central to market access.
• Paragraph IV litigation is not the principal barrier for a new conventional quinapril tablet.
• A new ANDA is more likely to face manufacturing, supply, pricing, and regulatory execution risks than patent litigation.
• Any patent strategy would need to focus on a new formulation, delivery system, manufacturing process, or use with a defensible claim scope.

Are there Paragraph IV challenges or Accupril patent litigation risks?

Paragraph IV challenges were relevant during the original generic entry period, when ANDA applicants could contest listed patents. That litigation cycle is no longer the principal commercial issue for standard quinapril tablets because the key original exclusivity period has expired.

Current risk remains in four areas:

1. A manufacturer may assert patents against a new formulation or combination product.
2. A generic applicant may face product-specific regulatory disputes over labeling or bioequivalence.
3. A manufacturer may challenge another supplier’s process or formulation patent outside the United States.
4. Supply interruptions can produce commercial exposure without any patent dispute.

No active, high-value U.S. patent litigation materially constraining ordinary quinapril tablets is identified in the public regulatory record reviewed for this analysis.

How should an excipient strategy address nitrosamine risk?

Nitrosamine control is the most important modern excipient issue for quinapril. FDA identified N-nitroso-quinapril concerns in quinapril products, and recalls or discontinuations have affected the product class. FDA’s nitrosamine guidance requires manufacturers to evaluate nitrosamine risks arising from active ingredients, excipients, water, processing conditions, packaging, and storage [4].

An Accupril-equivalent formulation should include a documented nitrosamine control strategy.

Excipient controls

Manufacturers should qualify excipient suppliers for:

• Nitrite and nitrate content.
• Amine impurities.
• Supplier process changes.
• Solvent and catalyst residues.
• Lot-to-lot variability.
• Storage humidity and temperature.
• Packaging interaction.

Excipients that can require particular scrutiny include lactose, crospovidone, gelatin, magnesium stearate, cellulose derivatives, and other materials with variable nitrite or secondary-amine impurity profiles. The risk assessment must be empirical rather than based only on excipient name.

Process controls

The development program should evaluate:

• Wet versus dry granulation.
• Exposure to heat and moisture.
• Hold times before compression.
• Lubrication time.
• Film-coating conditions.
• Residual solvents.
• Water quality.
• Packaging headspace and oxygen exposure.

Dry processing may reduce water-mediated degradation, but it can introduce blend and compression challenges. A wet process may improve granule uniformity while increasing chemical-stability risk. The optimal process depends on the selected excipient grades and impurity profile.

Packaging controls

Alu-Alu blister packaging or high-barrier bottles with desiccant may provide a stronger stability profile than conventional high-density polyethylene packaging. The commercial tradeoff is higher packaging cost, lower line speed, and possible patient-use inconvenience.

A manufacturer seeking premium positioning could differentiate through long-term stability, low-nitrosamine performance, and a validated high-barrier package rather than through a new active ingredient.

What formulation patents could support a new Accupril product?

A commercially relevant patent position would need to cover more than a routine excipient change. Potentially protectable areas include:

Low-nitrosamine quinapril tablets

A claim set could cover defined excipient impurity limits, a controlled alkaline microenvironment, and a demonstrated reduction in N-nitroso-quinapril under accelerated and long-term conditions. The patent would need carefully defined analytical thresholds and comparative data.

Moisture-protected tablets

A formulation using a specified coating, desiccant system, or low-moisture excipient combination could support claims directed to impurity control and shelf life. Packaging-only claims are generally weaker unless tied to a measurable product-performance result.

Modified-release quinapril

A sustained-release or delayed-release formulation could create a new product category, but it would require substantial pharmacokinetic and clinical development. Quinapril's established once- or twice-daily use limits the commercial justification for a complex delivery system.

Fixed-dose combinations

Quinapril/hydrochlorothiazide products, historically marketed as Accuretic, represent a more plausible line-extension opportunity than modified release. A new combination would require separate assessment of dose selection, dissolution, stability, labeling, and clinical relevance. The combination would compete with established ACE inhibitor/thiazide products and generic lisinopril/hydrochlorothiazide.

What commercial opportunities exist for Accupril generics?

1. Reliable generic supply

The strongest opportunity is dependable supply after product withdrawals, recalls, or manufacturer exits. Payers and wholesalers may value a supplier that maintains continuity across all four strengths and avoids repeated back orders.

2. Nitrosamine-controlled product

A supplier with validated low-nitrosamine performance could win contracts with hospitals, integrated delivery networks, and wholesalers. The advantage would be operational and regulatory rather than classic patent exclusivity.

3. Excipient substitution

Excipient substitution can improve cost, supply resilience, or stability. Candidates include:

• Replacing a constrained lactose grade.
• Using a lower-nitrite crospovidone grade.
• Optimizing the alkaline filler.
• Switching to a more robust lubricant system.
• Reducing coating complexity.
• Moving to a high-barrier blister.

The change must preserve pharmaceutical equivalence and bioequivalence. A major formulation change may require a suitability assessment, dissolution bridging, stability studies, and an ANDA supplement or new regulatory filing.

4. Contract manufacturing

Quinapril tablets are compatible with conventional high-volume oral-solid-dose manufacturing. Contract manufacturers can offer:

• Granulation and compression.
• Film coating.
• Bottle or blister packaging.
• Multi-strength production.
• Analytical testing for nitrosamines and degradation products.

The main barriers are validated process capability, reference-product matching, regulatory documentation, and demand predictability.

5. Institutional and international markets

The United States is a low-exclusivity market, but quinapril may retain value in selected international markets where local competition is less intense or where ACE inhibitor use remains substantial. Geographic entry requires country-specific review of:

• Patent status.
• Marketing authorization.
• Stability-zone requirements.
• Pharmacopoeial standards.
• Local bioequivalence rules.
• Reference-product availability.
• Government procurement pricing.

European and other regulated markets may require a decentralized or national generic filing. Emerging markets may offer lower development barriers but higher pricing pressure and collection risk.

How does Accupril compare with competing ACE inhibitors?

Product	Active ingredient	Generic maturity	Commercial assessment
Accupril	Quinapril	High	Niche opportunity; nitrosamine and supply execution are central
Zestril/Prinivil	Lisinopril	Very high	Larger generic base and broader prescribing familiarity
Vasotec	Enalapril	Very high	Established, low-cost alternative
Altace	Ramipril	High	Strong cardiovascular positioning in some markets
Capoten	Captopril	Very high	Older product with frequent dosing and lower premium potential

Quinapril faces substitution from lisinopril and enalapril. Any commercial strategy must therefore compete on availability, price, formulary status, and quality performance. A premium price for an otherwise conventional quinapril tablet is unlikely without documented supply or quality differentiation.

What is the FDA regulatory status of Accupril?

Quinapril hydrochloride tablets are FDA-approved prescription products. FDA-approved labeling includes contraindications involving angioedema history and use with certain interacting agents, including aliskiren in patients with diabetes and sacubitril/valsartan timing restrictions [1].

The regulatory status is commercially complicated by product availability. Brand Accupril has experienced market withdrawal or discontinuation activity, while generic quinapril products have faced supply and recall issues associated with N-nitroso-quinapril. A prospective manufacturer should distinguish:

• FDA approval of the active product.
• Commercial availability of a specific labeler’s product.
• Temporary shortage or recall status.
• Permanent brand discontinuation.
• Active ANDA status.
• Product-specific manufacturing compliance.

FDA Drug Shortages, Drugs@FDA, the Orange Book, and current labeling should be checked as separate records because they answer different regulatory questions [2,3,5].

What is the revenue exposure and market outlook?

Public sources do not provide a reliable current revenue figure for Accupril as a standalone brand. The revenue opportunity is more likely to come from generic volume than from brand pricing.

The principal commercial variables are:

• Number of active generic suppliers.
• Medicaid and commercial reimbursement.
• Wholesaler inventory requirements.
• FDA shortage conditions.
• Nitrosamine testing and release costs.
• Number of strengths manufactured.
• Packaging configuration.
• Hospital and government contract access.
• Competition from lisinopril, enalapril, ramipril, and ARBs.

A launch model should use conservative pricing, include recall and testing costs, and assume limited ability to charge a premium. The best near-term economics are likely in a focused, low-overhead product offering with all major strengths and a documented supply-quality advantage.

Key Takeaways

• Accupril is quinapril hydrochloride in immediate-release film-coated tablets.
• Original Accupril exclusivity has expired, and conventional quinapril tablets face established generic competition.
• The most important formulation issue is control of quinapril degradation and N-nitroso-quinapril formation.
• Magnesium carbonate and other excipients may affect stability, dissolution, and microenvironmental pH.
• A meaningful new patent position would require demonstrated technical differentiation, not routine excipient substitution.
• The strongest commercial opportunity is reliable, nitrosamine-controlled generic supply.
• Fixed-dose combinations and high-barrier packaging are more credible extensions than modified release.
• Biosimilar risk is irrelevant because quinapril is a chemically synthesized small molecule, not a biologic.
• U.S. commercial exposure depends more on supply, reimbursement, and competitive pricing than on patent litigation.
• Current FDA Orange Book, Drugs@FDA, labeling, and shortage records should control any launch or licensing decision.

FAQs

Is Accupril still available in the United States?

Brand availability has been limited by discontinuation and supply activity. Generic quinapril hydrochloride tablets may remain available from selected manufacturers, but availability is product- and labeler-specific.

Can a company file a generic quinapril tablet without challenging a patent?

Yes. Because the original Accupril exclusivity period has expired, a conventional ANDA may generally proceed without relying on a current Paragraph IV patent challenge, subject to the latest Orange Book record.

Does quinapril require biosimilar approval?

No. Quinapril is a synthetic small-molecule drug. The relevant pathway is an ANDA or another applicable small-molecule application, not a biosimilar application.

Which excipient is most likely to affect quinapril stability?

The overall excipient system matters, but alkaline fillers, moisture-sensitive components, and excipient nitrite impurities can materially affect stability and nitrosamine risk. No single excipient can be assessed independently from the manufacturing process and packaging.

Is a low-nitrosamine quinapril formulation patentable?

Potentially, if the formulation provides a non-obvious, reproducible reduction in nitrosamine formation and the claims define a credible composition or process. Routine supplier substitution without comparative technical data would provide a weaker patent position.

References

1. U.S. Food and Drug Administration. (2023). Accupril (quinapril hydrochloride) tablets: Prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. FDA.

5. U.S. Food and Drug Administration. (2024). FDA Drug Shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/